S T van Tiel Selected Research

Sarcoma (Soft Tissue Sarcoma)

12/2006	Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.
12/2004	Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.
5/2004	Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.
10/2002	Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
4/2002	Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
3/2001	Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.
11/2000	Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
7/2000	Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
2/2000	TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S T van Tiel Research Topics

Disease

9	Sarcoma (Soft Tissue Sarcoma) 12/2006 - 02/2000
8	Necrosis 12/2006 - 02/2000
4	Neoplasms (Cancer) 12/2004 - 07/2000
2	Neoplasm Metastasis (Metastasis) 01/2003 - 04/2002
2	Melanoma (Melanoma, Malignant) 04/2002 - 07/2000
2	Osteosarcoma (Osteogenic Sarcoma) 03/2001 - 02/2000
1	Leukocytosis (Pleocytosis) 03/2001
1	Adenocarcinoma 11/2000

Drug/Important Bio-Agent (IBA)

9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2004 - 02/2000
8	Melphalan (Alkeran)FDA LinkGeneric 12/2004 - 02/2000
2	CytokinesIBA 10/2002 - 03/2001
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2002 - 02/2000
1	Contrast MediaIBA 12/2004
1	liposomal doxorubicin (Doxil)FDA Link 05/2004
1	member 1 small inducible cytokine subfamily EIBA 10/2002
1	ParaffinIBA 10/2002
1	Thromboplastin (Tissue Factor)IBA 10/2002
1	Dactinomycin (Actinomycin)FDA LinkGeneric 04/2002
1	Interleukin-3 (Interleukin 3)IBA 03/2001
1	Histamine (Histamine Dihydrochloride)FDA Link 03/2001
1	Nitric Oxide Synthase (NO Synthase)IBA 11/2000
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 11/2000
1	SolutionsIBA 07/2000

Therapy/Procedure

2	Therapeutics 10/2002 - 03/2001
1	Limb Salvage 12/2006
1	Injections 03/2001
1	Intravenous Administration 03/2001
1	Drug Therapy (Chemotherapy) 07/2000